SAN DIEGO, April 16, 2025 ~ San Diego-based biotechnology company, NEUVOGEN, Inc., has announced the addition of two renowned experts in the field of immunology and cancer vaccines to their Scientific Advisory Board (SAB). Dr. James P. Allison, Ph.D., and Dr. Padmanee Sharma, M.D., Ph.D., have been appointed to provide guidance and expertise as the company continues to advance its next-generation cancer vaccine platform.

NEUVOGEN's Chief Executive Officer, Todd Binder, expressed excitement about the new appointments, stating that both Dr. Allison and Dr. Sharma are recognized pioneers and leaders in their respective fields. He also highlighted the impressive credentials of the existing SAB members, who cover a wide range of expertise in oncology, immunology, personalized cancer vaccines, and whole tumor cell vaccines.

Dr. Allison brings a wealth of knowledge and experience to NEUVOGEN's SAB as Regental Professor and Chair of Immunology at The University of Texas MD Anderson Cancer Center. He is also the Executive Director of the Immunotherapy Platform and Director of the James P. Allison Institute at MD Anderson. In 2018, he was awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work on cancer therapy by inhibiting negative immune regulation.

More on TelAve News

• "May the Fourth Be With You" Epic Star Wars Day Run/Walk in Alexandria, Va
• Museum Hack Presents Hacked Gala: A Rebellious Night of Art, Fashion, and Change at the Met
• Artist Séfora Camazano Honored with Prestigious Prize "The New Great Masters in New York"
• MoMojo Records announces posthumous album from Kip London
• Guests Can Save 20 Percent on a Florida Keys Vacation Home Rental with KeysCaribbean's 'Last-Minute Booking Discount'

Throughout his distinguished career, Dr. Allison has focused on studying T cell responses and developing strategies for cancer immunotherapy. His contributions have had a significant impact on the field and have led to numerous accolades and awards.

Joining Dr. Allison on NEUVOGEN's SAB is Dr. Padmanee Sharma, who holds multiple positions at MD Anderson including Professor of Genitourinary Medical Oncology and Immunology, Director of Scientific Programs for the James P. Allison Institute, Scientific Director of the Immunotherapy Platform, and T.C. and Jeanette Hsu Endowed Chair in Cell Biology.

Dr. Sharma is a member of several prestigious organizations such as the American Society for Clinical Investigation (ASCI) and has received numerous awards for her groundbreaking research in tumor immunology. She is also a pioneer in the field of immune checkpoint therapy, which has revolutionized cancer treatment.

A full list of NEUVOGEN's SAB members, along with their comprehensive biographies, can be found on the company's website at www.neuvogen.com/about-us/. With the guidance and expertise of these distinguished experts, NEUVOGEN is committed to advancing its platform capability and delivering a wide range of targets to activate cytotoxic T cells. This will build upon the recent success seen with cancer vaccines that have a lesser breadth of targets.

---

Show All News | Report Violation